FI954402A - Uusi farmaseuttinen tuote - Google Patents

Uusi farmaseuttinen tuote Download PDF

Info

Publication number
FI954402A
FI954402A FI954402A FI954402A FI954402A FI 954402 A FI954402 A FI 954402A FI 954402 A FI954402 A FI 954402A FI 954402 A FI954402 A FI 954402A FI 954402 A FI954402 A FI 954402A
Authority
FI
Finland
Prior art keywords
pharmaceutical product
new pharmaceutical
new
product
pharmaceutical
Prior art date
Application number
FI954402A
Other languages
English (en)
Swedish (sv)
Other versions
FI954402A0 (fi
FI112226B (fi
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Iii John Mcneill Mcgill
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI954402(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI954402A0 publication Critical patent/FI954402A0/fi
Publication of FI954402A publication Critical patent/FI954402A/fi
Application granted granted Critical
Publication of FI112226B publication Critical patent/FI112226B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI954402A 1994-09-19 1995-09-18 Ei solvatoitu, kiteinen 6-hydroksi-2-(4-hydroksifenyyli)-3-[4-(2-piperidinoetoksi)bentsoyyli]bentso[b]tiofeenihydrokloridi FI112226B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US30832594 1994-09-19
US42791495A 1995-04-26 1995-04-26
US42791495 1995-04-26

Publications (3)

Publication Number Publication Date
FI954402A0 FI954402A0 (fi) 1995-09-18
FI954402A true FI954402A (fi) 1996-03-20
FI112226B FI112226B (fi) 2003-11-14

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
FI954402A FI112226B (fi) 1994-09-19 1995-09-18 Ei solvatoitu, kiteinen 6-hydroksi-2-(4-hydroksifenyyli)-3-[4-(2-piperidinoetoksi)bentsoyyli]bentso[b]tiofeenihydrokloridi
FI954403A FI121424B (fi) 1994-09-19 1995-09-18 Menetelmä 6-hydroksi-2-(4-hydroksifenyyli)-3-[4-(2-piperidinoetoksi)-bentsoyyli]bentso[b]tiofeenihydrokloridin kiteisen solvaatin valmistamiseksi ja kiteiset 1,2-dikloorietaani- ja 1,2,3-triklooripropaanisolvaatit

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI954403A FI121424B (fi) 1994-09-19 1995-09-18 Menetelmä 6-hydroksi-2-(4-hydroksifenyyli)-3-[4-(2-piperidinoetoksi)-bentsoyyli]bentso[b]tiofeenihydrokloridin kiteisen solvaatin valmistamiseksi ja kiteiset 1,2-dikloorietaani- ja 1,2,3-triklooripropaanisolvaatit

Country Status (51)

Country Link
US (4) US5731327A (fi)
JP (2) JPH08193081A (fi)
KR (2) KR100381346B1 (fi)
CN (2) CN1068324C (fi)
AP (1) AP754A (fi)
AT (2) AT502957A1 (fi)
AU (3) AU692907B2 (fi)
BE (2) BE1009625A3 (fi)
BG (1) BG62793B1 (fi)
BR (2) BR9504059A (fi)
CA (2) CA2158399C (fi)
CH (3) CH691594A5 (fi)
CO (2) CO4410190A1 (fi)
CZ (2) CZ292007B6 (fi)
DE (3) DE19534744A1 (fi)
DK (4) DK175903B1 (fi)
EE (1) EE03386B1 (fi)
EG (1) EG23763A (fi)
ES (2) ES2109882B1 (fi)
FI (2) FI112226B (fi)
FR (2) FR2732020B1 (fi)
GB (2) GB2293382B (fi)
GE (1) GEP19991821B (fi)
GR (2) GR1002697B (fi)
HK (1) HK1019009A1 (fi)
HR (2) HRP950483B1 (fi)
HU (2) HU225417B1 (fi)
IE (2) IE80883B1 (fi)
IL (3) IL125283A (fi)
IS (1) IS1788B (fi)
IT (2) IT1277602B1 (fi)
LU (2) LU88660A1 (fi)
LV (2) LV11178B (fi)
MY (1) MY116371A (fi)
NL (2) NL1001194C2 (fi)
NO (2) NO308107B1 (fi)
NZ (2) NZ280027A (fi)
OA (1) OA10406A (fi)
PE (2) PE32796A1 (fi)
PL (2) PL182450B1 (fi)
PT (2) PT101771B (fi)
RO (2) RO115259B1 (fi)
RS (2) RS49578B (fi)
SE (2) SE509265C2 (fi)
SI (2) SI9500293A (fi)
SK (1) SK283502B6 (fi)
TR (1) TR199501136A2 (fi)
TW (1) TW412534B (fi)
UA (2) UA42716C2 (fi)
UY (1) UY24040A1 (fi)
WO (1) WO1996009045A1 (fi)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
EA001257B1 (ru) * 1996-03-26 2000-12-25 Эли Лилли Энд Компани Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA979720B (en) 1996-10-30 1999-04-29 Lilly Co Eli Prophylaxis of breast cancer
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US6921827B2 (en) * 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB2456096B (en) * 2006-10-17 2011-08-17 Cipla Ltd Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
US20090023799A1 (en) * 2007-07-20 2009-01-22 George Laurence CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009150669A1 (en) * 2008-06-09 2009-12-17 Erregierre S.P.A. Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4358593A (en) 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
NZ200204A (en) 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW275584B (fi) * 1993-06-24 1996-05-11 Fli Lilly And Co
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
NL1001196A1 (nl) 1996-03-19
SE520721C2 (sv) 2003-08-12
BE1009626A3 (fr) 1997-06-03
SE9503214L (sv) 1996-03-20
IL125283A (en) 2001-06-14
CZ240395A3 (en) 1996-04-17
FI954402A0 (fi) 1995-09-18
US20020173645A1 (en) 2002-11-21
SE509265C2 (sv) 1998-12-21
YU61495A (sh) 1998-05-15
AU3173195A (en) 1996-04-04
AU692907B2 (en) 1998-06-18
IL115314A (en) 2000-02-29
LV11177B (en) 1996-08-20
SK23397A3 (en) 1997-08-06
ITMI951936A0 (it) 1995-09-15
DK2897A (da) 1997-01-09
IS4446A (is) 1997-03-18
SI9500292A (en) 1996-06-30
MY116371A (en) 2004-01-31
GB2293602A (en) 1996-04-03
KR100381346B1 (ko) 2004-04-13
WO1996009045A1 (en) 1996-03-28
UY24040A1 (es) 1996-03-07
IT1277602B1 (it) 1997-11-11
NZ280028A (en) 1997-05-26
AT407988B (de) 2001-07-25
IL115314A0 (en) 1996-05-14
HRP950482A2 (en) 1998-02-28
CA2158400A1 (en) 1996-03-20
NO313996B1 (no) 2003-01-13
CA2158399A1 (en) 1996-03-20
HK1019009A1 (en) 2000-01-14
US6472531B1 (en) 2002-10-29
IL115315A0 (en) 1995-12-31
GR1002709B (el) 1997-06-04
BG62793B1 (bg) 2000-08-31
LV11178B (en) 1996-08-20
DE19549755B4 (de) 2005-05-04
IL115315A (en) 1999-09-22
FI121424B (fi) 2010-11-15
HUT74178A (en) 1996-11-28
GB9519028D0 (en) 1995-11-15
HRP950483B1 (en) 2003-02-28
NO953657L (no) 1996-03-20
OA10406A (en) 2001-12-05
GB2293602B (en) 1998-05-06
ITMI951935A0 (it) 1995-09-15
IT1277601B1 (it) 1997-11-11
CZ292007B6 (cs) 2003-07-16
PL310518A1 (en) 1996-04-01
TW412534B (en) 2000-11-21
PT101771B (pt) 1997-04-30
KR100367376B1 (ko) 2003-03-06
FR2732020B1 (fr) 1997-11-14
CH691125A5 (de) 2001-04-30
BR9504059A (pt) 1996-09-24
RO115259B1 (ro) 1999-12-30
CH691594A5 (de) 2001-08-31
CZ240295A3 (en) 1996-04-17
TR199501136A2 (tr) 1996-06-21
RS49513B (sr) 2006-10-27
LV11178A (lv) 1996-04-20
UA42716C2 (uk) 2001-11-15
DK102895A (da) 1996-03-20
NO953658D0 (no) 1995-09-15
ITMI951936A1 (it) 1997-03-15
AU3173095A (en) 1996-04-04
NL1001194A1 (nl) 1996-03-19
FI954403A (fi) 1996-03-20
LV11177A (lv) 1996-04-20
NO953658L (no) 1996-03-20
AP754A (en) 1999-07-22
RO115260B1 (ro) 1999-12-30
CN1068324C (zh) 2001-07-11
AT502957A1 (de) 2007-06-15
BR9504060A (pt) 1996-09-24
HU9502721D0 (en) 1995-11-28
KR960010634A (ko) 1996-04-20
ES2109882A1 (es) 1998-01-16
HUT75033A (en) 1997-03-28
GB9519032D0 (en) 1995-11-15
JP2860071B2 (ja) 1999-02-24
NL1001196C2 (nl) 1997-04-04
GEP19991821B (en) 1999-11-05
HU9502723D0 (en) 1995-11-28
ITMI951935A1 (it) 1997-03-15
CO4410191A1 (es) 1997-01-09
LU88661A1 (fr) 1996-07-15
PL182450B1 (pl) 2002-01-31
US6399778B1 (en) 2002-06-04
GR1002697B (el) 1997-05-22
PT101770B (pt) 1997-04-30
PE14796A1 (es) 1996-05-19
JPH08193081A (ja) 1996-07-30
PT101771A (pt) 1996-04-30
PL310517A1 (en) 1996-04-01
YU61395A (sh) 1998-09-18
DK175903B1 (da) 2005-06-06
NZ280027A (en) 1997-05-26
DK102795A (da) 1996-03-20
GB2293382A (en) 1996-03-27
FR2724655A1 (fr) 1996-03-22
ES2129293B1 (es) 2000-01-16
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
FI112226B (fi) 2003-11-14
NL1001194C2 (nl) 1997-04-04
ES2109882B1 (es) 1998-08-16
DK2797A (da) 1997-01-09
CN1132205A (zh) 1996-10-02
ATA154295A (de) 2000-12-15
AU691955B2 (en) 1998-05-28
IE80883B1 (en) 1999-05-19
CA2158400C (en) 2006-10-24
NO953657D0 (no) 1995-09-15
NO308107B1 (no) 2000-07-24
SE9503213L (sv) 1996-03-20
LU88660A1 (fr) 1996-07-15
BG101242A (en) 1998-03-31
HRP950483A2 (en) 1997-10-31
RS49578B (sr) 2007-04-10
CO4410190A1 (es) 1997-01-09
JPH08176147A (ja) 1996-07-09
DK175887B1 (da) 2005-05-23
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
UA44240C2 (uk) 2002-02-15
DK175897B1 (da) 2005-05-30
FR2724655B1 (fr) 1997-11-14
IE950721A1 (en) 1996-03-20
SK283502B6 (sk) 2003-08-05
PL187686B1 (pl) 2004-09-30
CZ290343B6 (cs) 2002-07-17
EE9700055A (et) 1997-08-15
EE03386B1 (et) 2001-04-16
DE19534745B4 (de) 2004-06-09
DE19534744A1 (de) 1996-03-21
PT101770A (pt) 1996-04-30
DK175886B1 (da) 2005-05-23
CH691478A5 (de) 2001-07-31
SE9503213D0 (sv) 1995-09-15
US5731327A (en) 1998-03-24
GB2293382B (en) 1998-08-19
PE32796A1 (es) 1996-08-07
BE1009625A3 (fr) 1997-06-03
HU225417B1 (en) 2006-11-28
IE950722A1 (en) 1996-03-20
CN1075069C (zh) 2001-11-21
ES2129293A1 (es) 1999-06-01
DE19534745A1 (de) 1996-04-04
KR960010637A (ko) 1996-04-20
HU227683B1 (en) 2011-11-28
AP9700938A0 (en) 1997-04-30
SI9500293A (en) 1996-06-30
SE9503214D0 (sv) 1995-09-15
CN1127253A (zh) 1996-07-24
HRP950482B1 (en) 2007-04-30
FR2732020A1 (fr) 1996-09-27
FI954403A0 (fi) 1995-09-18

Similar Documents

Publication Publication Date Title
FI954402A0 (fi) Uusi farmaseuttinen tuote
FI971279A0 (fi) Lääkkeitä
BR9610214A (pt) Compostos farmacéuticos
BR9508339A (pt) Medicamento
DK0813586T3 (da) Mugfjernelsesprodukt
DK0683987T3 (da) Kødprodukt
BR9507768A (pt) Composição farmacêutica
ITMI941169A0 (it) Formulazioni farmaceutiche
DK86492D0 (da) Laegemiddel
FI973230A (fi) Uusi farmaseuttinen formulaatio
FI951155A0 (fi) Farmaseuttinen valmiste
BR9711981A (pt) Produto farmac-utico cristalino
NO965448D0 (no) Farmasöytiske forbindelser
DE69519622D1 (de) Radiographisches Erzeugnis
AU126984S (en) Pharmaceutical product
MD150B1 (ro) Produs curativoprofilactic
UA1090S (uk) Фармацевтичний виріб
DK128993D0 (da) Laegemiddel/-plante
DE9421173U1 (de) Schneidfähiges Fleischprodukt
SE9402924D0 (sv) Novel pharmaceutical composition
UA25976C2 (uk) Противиразковий лікарський препарат
DK137192D0 (da) Laegemiddel/-plante
NO962816D0 (no) Farmasöytiske forbindelser
KR950024914U (ko) 제품 분할 장치
LV11093A (lv) Marcipana izstradajumi

Legal Events

Date Code Title Description
MM Patent lapsed